黄芪注射液佐治心血管疾病临床观察  

Clinical Evaluation of Huangqi Injection in the Adjuvant Treatment of Cardiovascular Diseases

作　　者：王淑芳 WANG Shufang(Ordos Hospital of Traditional Chinese Medicine,Ordos,Inner Mongolia,China 017010)

机构地区：[1]内蒙古自治区鄂尔多斯市中医医院,内蒙古鄂尔多斯017010

出　　处：《中国药业》2024年第S02期65-67,共3页China Pharmaceuticals

摘　　要：目的探讨黄芪注射液佐治心血管疾病的临床疗效。方法选取医院2020年1月至2021年1月收治的心血管疾病患者60例,按双盲法分为对照组和观察组,各30例。两组患者均予常规西药治疗,观察组患者加用黄芪注射液。结果观察组临床总有效率为93.33%,显著高于对照组的73.33%(P<0.05)。观察组患者治疗后的总胆固醇、甘油三酯水平均显著低于对照组,高密度脂蛋白胆固醇水平显著高于对照组(P<0.05);全血黏度、血浆黏度、纤维蛋白原水平均显著低于对照组(P<0.05)。结论黄芪注射液佐治心血管疾病,可进一步降低机体血脂水平,改善血液流变学。Objective To investigate the clinical efficacy of Huangqi Injection in the adjuvant treatment of cardiovascular diseases.Methods A total of 60 patients with cardiovascular diseases admitted to the hospital from January 2020 to January 2021 were selected and divided into the control group and the observation group by the double-blind method,with 30 cases in each group.The patients in the two groups were treated with conventional western medicines,on this basis,the patients in the observation group were treated with Huangqi Injection.Results The total clinical effective rate in the observation group was 93.33%,which was significantly higher than 73.33%in the control group(P<0.05).After treatment,the total cholesterol and triglyceride levels in the observation group were significantly lower than those in the control group,and the high-density lipoprotein cholesterol level was significantly higher than that in the control group(P<0.05);the whole blood viscosity,plasma viscosity and fibrinogen levels were significantly lower than those in the control group(P<0.05).Conclusion Huangqi Injection can further reduce blood lipid levels and improve hemorheology in the adjuvanttreatment of cardiovascular diseases.

关 键 词：心血管疾病 黄芪 血液流变学 血脂 临床疗效 

分 类 号：R932[医药卫生—生药学] R285.6[医药卫生—药学]